Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells 10,000 Shares of Stock

Merck & Co., Inc. (NYSE:MRK) EVP Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the sale, the executive vice president directly owned 36,613 shares of the company’s stock, valued at $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Chirfi Guindo also recently made the following trade(s):

• On Thursday, August 6th, Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00.

Merck & Co., Inc. Trading Up 2.0%

Shares of MRK traded up $2.65 during mid-day trading on Thursday, reaching $135.57. The stock had a trading volume of 8,891,161 shares, compared to its average volume of 10,698,836. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $135.68. The firm has a market cap of $334.49 billion, a price-to-earnings ratio of 108.46, a P/E/G ratio of 5.62 and a beta of 0.19. The business’s fifty day moving average is $124.94 and its 200 day moving average is $119.64. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the firm earned $2.13 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.5%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on MRK shares. CICC Research assumed coverage on Merck & Co., Inc. in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price on the stock. Barclays raised their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings lowered shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Citigroup assumed coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Fifteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $135.50.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Higher valuation estimates: Analysts’ price-target range has moved toward approximately $140–$155, while a reported fair-value estimate increased from $132.78 to $136.85. Analysts cited pipeline progress, business-development activity and a focus on late-stage therapies. Merck fair value and pipeline progress article
• Positive Sentiment: Analyst upgrade: Daiwa Securities raised Merck from “neutral” to “outperform” and set a $143 price target, implying further upside based on the provided reference price. Daiwa Securities analyst update
• Positive Sentiment: Strong market momentum: MRK touched a new all-time high of $135.68 alongside other large-cap stocks, signaling continued buying interest and positive short-term momentum. Merck reaches an all-time high article
• Positive Sentiment: Earnings expectations improved: Erste Group lifted its FY2026 EPS estimate to $2.75 from $2.70, close to the $2.77 consensus forecast. Recent quarterly revenue also exceeded expectations, supported by oncology and Animal Health sales.
• Neutral Sentiment: Keytruda remains pivotal: Keytruda continues to drive growth through demand in early-stage and metastatic cancers, but investors are weighing whether that momentum can continue through the second half of 2026. Keytruda growth outlook article
• Negative Sentiment: Patent and competition risks: Future Keytruda patent loss and increasing competition could pressure Merck’s largest revenue driver, making pipeline execution important to sustaining long-term growth. Zacks Keytruda outlook article
• Negative Sentiment: Insider selling: EVP Richard Deluca sold multiple blocks totaling roughly 45,000 shares over August 10–12, while EVP Jennifer Zachary sold 80,315 shares. Although both executives retained shares, the transactions may modestly weigh on sentiment. Merck insider selling article

Hedge Funds Weigh In On Merck & Co., Inc.

Several institutional investors have recently bought and sold shares of MRK. Osbon Capital Management LLC acquired a new position in shares of Merck & Co., Inc. in the second quarter valued at approximately $279,000. LM Advisors LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $1,814,000. TrinityBridge Ltd purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $446,000. Jupiter Wealth Management LLC purchased a new position in Merck & Co., Inc. in the 2nd quarter valued at approximately $1,773,000. Finally, OVERSEA CHINESE BANKING Corp Ltd acquired a new position in shares of Merck & Co., Inc. in the second quarter worth $969,000. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.